In Vitro Activity of Human Immunodeficiency Virus Protease Inhibitors against Pneumocystis carinii

Since 1996, the introduction of protease inhibitors (PIs) has led to a dramatic decrease of human immunodeficiency virus—related Pneumocystis carinii pneumonia. This effect is clearly due, in large part, to the induction of immune reconstitution by highly active antiretroviral therapy (HAART). Howev...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2000-05, Vol.181 (5), p.1629-1634
Main Authors: Atzori, Chiara, Angeli, Elena, Mainini, Annalisa, Agostoni, Fiorenza, Micheli, Valeria, Cargnel, Antonietta
Format: Article
Language:English
Subjects:
AIDS/HIV
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antifungal agents
Biological and medical sciences
Cell Line
Gels
Highly active antiretroviral therapy
HIV
HIV Protease Inhibitors - pharmacology
Human immunodeficiency virus
Humans
Indinavir - pharmacology
Lung
Major Articles
Male
Medical sciences
Microbial Sensitivity Tests
Nelfinavir - pharmacology
Pepstatins - pharmacology
Pharmacology. Drug treatments
Pneumocystis
Pneumocystis - drug effects
Pneumocystis - isolation & purification
Pneumocystis carinii
Pneumocystis Infections - microbiology
Pneumocystis pneumonia
Protease inhibitors
Rats
Rats, Sprague-Dawley
Saquinavir - pharmacology
T lymphocytes
Trophozoites
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since 1996, the introduction of protease inhibitors (PIs) has led to a dramatic decrease of human immunodeficiency virus—related Pneumocystis carinii pneumonia. This effect is clearly due, in large part, to the induction of immune reconstitution by highly active antiretroviral therapy (HAART). However, it is conceivable that PIs had other beneficial effects, including direct activity against Pneumocystis. In this study, the occurrence of specific aspartyl proteases in Pneumocystis is described. These protease targets seemed to be affected in vitro by antiretroviral PIs. These data suggest intriguing implications for the possible antipneumocystis benefit of receiving indinavir, ritonavir, nelfinavir, or saquinavir during HAART.
ISSN:0022-1899
1537-6613
DOI:10.1086/315437